Generic drugs in cardiology: will they reduce health care costs?  by Pitt, Bertram
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eneric Drugs in Cardiology:
ill They Reduce Health Care Costs?
ertram Pitt, MD
nn Arbor, Michigan
The introduction of generic drugs should lower health care costs by reducing the price of
drugs. The realization of this goal may, however, not be fully achieved: generic drugs may be
underused or misused in comparison to prescription drugs because of a lack of ongoing
postgraduate physician education. More importantly, there is little incentive to explore
new indications for soon-to-be generic drugs and drugs that are already generic. The
failure to explore new indications for soon-to-be and existing generic drugs may result in
a missed opportunity to further reduce health care costs. Thus, the apparent savings
resulting from the introduction of generic drugs may not be fully realized unless the
government and other third-party payers take a more active role in postgraduate drug
education and investigation. (J Am Coll Cardiol 2004;44:10 –3) © 2004 by the
American College of Cardiology Foundationt
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aublic pressure to increase the availability of low-cost
eneric drugs and, therefore, lower health care costs is
rowing. The realization that the cost of prescription drugs
akes up an increasingly large percentage of health care
osts of the elderly has focused government and other
hird-party payers on this problem. The ability of generic
rug manufacturers to bring generic versions of prescription
rugs to market recently has been facilitated, and delaying
actics previously used by prescription drug manufacturers
ave been severely limited. Pressure to further facilitate the
vailability of generic drugs is likely to increase during the
ext several years as some form of prescription drug benefits
ecomes part of Medicare. Reducing health care costs with
eneric drugs while maintaining quality of care is an
mportant societal goal. To achieve this objective, however,
ertain issues must be addressed. First, generic drugs, as
escribed in the following text, are more likely to be
nderused or misused than their prescription counterparts.
hus, the potential cost savings associated with their use
ay not be realized, and in some instances health care costs
ay actually increase. Second, the lack of patent protection
ay lessen the incentive to compare generic drugs with
on-generic members of the same class and with non-
eneric drugs of another class. There is also little incentive
o explore new indications for some soon-to-be generic
rugs or drugs that are already generic. This may also have
mportant implications for health care costs because oppor-
unities to reduce morbidity and mortality in a cost-effective
anner are missed. The apparent savings resulting from the
ntroduction of generic drugs, therefore, may turn out to be
llusory unless the government and other third-party payers
From the University of Michigan School of Medicine, Ann Arbor, Michigan. Dr.
itt is a consultant to Merck, Pfizer, Sankyo, Takeda, Astra Zeneca, and Novartis, is
n the board of directors of IVAX Pharmaceuticals, and holds stock in that company.cManuscript received September 5, 2003; accepted February 5, 2004.ake a more active role in postgraduate drug education and
nvestigation.
NDERUSE AND MISUSE OF GENERIC DRUGS
espite compelling evidence from major randomized stud-
es, guidelines by organizations such as the American
ollege of Cardiology/American Heart Association (ACC/
HA), and local critical care pathways, many major cardio-
ascular drugs, such as angiotensin-converting enzyme
ACE) inhibitors and beta-blockers in patients with heart
ailure (HF) due to systolic left ventricular (LV) dysfunction
nd statins in patients with known vascular disease, are
nderused (1,2). This underuse has many causes, which
ave been reviewed elsewhere (3), and occurs despite journal
dvertising, postgraduate seminars, and drug detailing.
When a drug, such as the ACE inhibitor enalapril,
ecomes generic, the interest of the prescription drug
anufacturer is reduced because third-party payers reduce
eimbursement, limit access, and/or increase co-payments
n the non-generic version. Pharmaceutical companies
aking other non-generic members of the class are forced
o increase spending on marketing on ancillary properties of
he drug, which may or may not have any major effect on
fficacy, safety, or cost effectiveness. The class itself may
eceive less attention in the market place and may gradually
e replaced by newer, more expensive, although not neces-
arily more effective, drugs of other classes. For example,
CE inhibitors, although effective and widely used in
atients with essential hypertension, have decreased their
ate of growth in comparison with angiotensin receptor-
locking agents. The potential cost savings from generic
CE inhibitors in patients with essential hypertension,
herefore, may not be fully realized as physicians switch to
ngiotensin receptor blockers and other newer more costly
lasses of drugs.
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July 7, 2004:10–3 Generic Drugs in CardiologyAn example of the misuse of a generic drug is spirono-
actone. The results of the Randomized Aldactone Evalua-
ion Study (RALES) trial (4) showing a reduction in total
ortality and in hospitalization for HF in patients with
evere HF due to systolic LV dysfunction randomized to
pironolactone has led to its increasing use in patients with
evere HF. These results were of particular importance
ecause spironolactone is generic and available in most parts
f the world at a cost of only a few cents a day. Although the
xcess incidence of serious hyperkalemia (serum potassium
6.0 mEq/l) in the RALES trial (4) was only 1% and there
ere no deaths attributable to hyperkalemia in patients
andomized to spironolactone. Since publication, there have
een a number of reports of serious hyperkalemia associated
ith spironolactone use in patients with HF, resulting in
enal dysfunction, hospitalization, the need for dialysis, and
n some instances, death (5–10). An analysis of these
eports, however, reveals that a large percentage of the
dverse events occurred with dosages other than those
ecommended in the RALES trial (25 mg daily) (4), in
atients excluded from the trial because of renal dysfunction
creatinine 2.5 mg/dl or K 5 mEq/l), and/or a failure
o monitor serum potassium and to adjust the dose of
pironolactone according to the level of serum potassium as
ecommended in the original report.
Although it is difficult to calculate the exact costs of the
dverse effects associated with the use of spironolactone in
atients with chronic HF, it would appear that the costs
aved by using generic spironolactone compared, for exam-
le, with the costs associated with a non-generic angiotensin
eceptor blocker may have been more than offset by these
dverse events. In large part, these adverse events are
voidable and attributable to a lack of physician education
nvolving the indications, dosing, and monitoring of spi-
onolactone. Because spironolactone is generic, there have
een no large-scale media advertising or pharmaceutical
epresentative “detailing” efforts focused on the practicing
hysician and relatively little postgraduate education. Sev-
ral other cardiovascular drugs are, or will soon be, available
n generic form. The risks associated with several of these
rug classes are less than with spironolactone; nevertheless,
he potential for underuse or misuse of these agents poses an
mportant public health problem. The cost to society re-
arding underuse of effective drugs such as ACE inhibitors,
eta-blockers, and statins may in fact be far greater than that
or misuse of drugs such as spironolactone.
Abbreviations and Acronyms
ACC/AHA  American College of Cardiology/
American Heart Association
ACE  angiotensin-converting enzyme
HF  heart failure
LV  left ventricular
RALES  Randomized Aldactone Evaluation StudyMost drug information in postgraduate education in the n.S. comes from the pharmaceutical industry. Therefore,
here is little information available on an ongoing basis to
he physician concerning generic drugs. If we wish to realize
he potential health care savings associated with generic
rugs, we need to consider a change in the quality of drug
nformation and the availability of funding for postgraduate
ducation. Society, government, and third-party payers
enefit from inexpensive generic drugs. They should there-
ore insure that these drugs are used effectively and safely.
ontinuing physician education is important in assuring
ppropriate use of drugs in eligible individuals.
One approach would be for the government and/or
hird-party payers to provide direct grant support to univer-
ities and/or organizations such as the ACC/AHA to
nsure unbiased medical education concerning the indica-
ions, dosing, and monitoring of generic drugs. Consider-
tion might also be given to funding an independent force
o “detail” generic drugs (academic detailing) to the prac-
icing physician because this approach appears to be one of
he most effective means of influencing physician behavior.
cademic detailing recently has been shown to be effective
n assuring the appropriate use of drugs in patients with
ssential hypertension (11). Failure of the government and
hird-party payers to meet this challenge and leave the
mpetus for postgraduate education to the pharmaceutical
ndustry, which has an incentive to shift physician use of
rugs to more expensive, although not necessarily more
ffective, non-generic drugs, may negate any potential sav-
ngs from generic drugs and in some instances may actually
ake generic drug use more expensive than non-generic
rescription drugs. Other quality-assurance approaches such
s the “check-off” system used to increase the use of
eta-blockers and ACE inhibitors in patients postinfarction
r in HF due to systolic LV dysfunction also may be
ffective. The later approach, although addressing the issue
f underuse of generic drugs, will not alter the potential for
nderdosing and misuse, at least until improved information
ystems are more generally available that allow detailed
nformation on indications and contraindications, dosing,
nd drug monitoring procedures to be easily collated.
MPACT OF SOON-TO-BE AND
ENERIC DRUGS ON DRUG DEVELOPMENT
here are other less apparent costs to society of generic
rugs or soon-to-be generic drugs that may be even more
ostly in the long run than the underuse and the misuse of
eneric drugs outlined in the preceding text. For example,
everal ACE inhibitors are generic, and there is relatively
ittle investment in clinical trials to compare their cost
ffectiveness to other non-generic members of the class,
hich have been claimed to have special advantages such as
tissue specificity,” or to newer agents of another class such
s the angiotensin receptor blockers. Increased funding is
eeded for these comparative cost-effectiveness studies if
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Generic Drugs in Cardiology July 7, 2004:10–3hysicians are to reach an informed conclusion amidst the
any conflicting claims.
There also is relatively little incentive in exploring new
ndications for generic or soon-to-be generic drugs. For
xample, there is no incentive to invest in clinical trials of
eneric ACE inhibitors for new indications whereas angio-
ensin receptor-blocking agents, which have remaining
atent protection, are under active investigation for several
ew indications. The RALES trial (3,4) demonstrated the
ffectiveness of aldosterone blockade in patients with severe
F. There has, however, been relatively little use of spi-
onolactone in patients with mild-to-moderate HF, even
hough there is increasing data to suggest that aldosterone
lockade improves ventricular remodeling and endothelial
ysfunction and decreases collagen formation and ventric-
lar arrhythmias in patients with mild-to-moderate HF due
o systolic LV dysfunction (12–16). The lack of well-
esigned, large-scale randomized trials of this drug in these
ndividuals precludes its recommendation and inclusion in
uidelines and hence its widespread use. Aldosterone block-
de may also have an important role in patients with
symptomatic systolic LV dysfunction, HF due to preserved
ystolic function, hypertension, and a variety of other
ardiovascular conditions. The potential health care savings
f aldosterone blockade was shown to be effective in reduc-
ng morbidity and mortality in these conditions by even a
alf of that observed in RALES (4) would be enormous.
his benefit is unlikely to be realized because there is no
ncentive for pharmaceutical companies to invest in further
rials of a generic agent such as spironolactone.
One potential solution would be to allow pharmaceutical
anufactures who have a prescription drug nearing the end
f its patent life to apply to an independent commission
ith representatives from the Food and Drug Administra-
ion, third-party payers, the academic community, and the
ublic to extend patent life based upon the potential savings
n health care costs and lives saved from the proposed
ndication. Although this approach could lead to frivolous
equests for patent extension, the potential benefits, likeli-
ood of success, and the effect on public health could be
eighed by the commission and assessed prospectively. The
harmaceutical manufacturer would bear the costs of the
roposed trial and reap the potential profit should the trial
e successful. The extension of a patent for example by a few
ears for a “blockbuster” drug could result in millions of
ollars profit for the manufacturer and justify an investment
n a new indication but more importantly could result in an
ven greater reduction in health care costs and lives. The
xtension of patent life to promote investment in new
otentially cost-effective indications for a soon-to-be ge-
eric drug may not be politically obtainable and other
olutions may be necessary. However, failure to explore new
pproaches to this problem may negate much of the
otential cost savings to society associated with the intro-
uction of lower cost generic drugs.
For a drug that is already generic, such as spironolactone,different solution is necessary. In this instance, funding for
urther clinical indications should be available through the
ational Institutes of Health or other third-party payers.
unding is currently available for large-scale drug trials
hrough the National Institutes of Health but is inadequate
o address many of the issues we currently have in cardiol-
gy. The cost of large-scale randomized trials is large.
herefore, it would be desirable if Congress were to set
side funding for such a program in a special account to
void the controversy concerning whether these funds
ould be better spent for basic research. If we are to truly
ealize further potential health care savings from generic
rugs, we will need to adequately fund clinical research into
heir use. This is not to deny the long-term benefits of basic
esearch for health care costs but rather to emphasize that
e need both approaches.
The problems outlined in this report are likely to increase
s more cardiovascular drugs become available as generic.
lthough we should welcome new classes of drugs that
rovide further health care benefits and cost savings, we
hould be certain that we do not discard old “generic” drugs
nd strategies that may be as, or even more, beneficial and
ossibly more cost effective than newer ones.
eprint requests and correspondence: Dr. Bertram Pitt, 1500
ast Medical Center Drive, 3214 Taubman Center, Ann Arbor,
ichigan 48109. E-mail: Bpitt@umich.edu.
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